Bayer flags major Phase III results for stroke prevention drug asundexian
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
Collaboration integrates AJICAP™ technology with global manufacturing capabilities to streamline antibody-drug conjugate pipelines
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
One Health-based surveillance model to focus on bird sanctuaries and high-risk human populations
American College of Cardiology and Korean Society of Cardiology convene global experts to address rising cardiometabolic burden
4th World Homoeopathy Summit at Palace of Westminster and University of Oxford spotlights integrative healthcare and global collaboration
The company reported net revenue of SEK 13.5 million for the full year 2025
The national platform brought together healthcare professionals, patient advocates, and stakeholders
Discussions will focus on how private space stations can improve access, repeatability and commercial feasibility for advanced biotech experiments
The new outpatient-focused clinic is designed to address voice, airway and swallowing disorders through advanced diagnostics
Subscribe To Our Newsletter & Stay Updated